Resultado de búsqueda
Chlorodehydromethyltestosterone (CDMT; brand name Oral Turinabol), also known as 4-chloro-17β-hydroxy17α-methylandrosta-1,4-dien-3-one, is an anabolic–androgenic steroid (AAS). It is the 4-chloro-substituted derivative of metandienone (dehydromethyltestosterone).
- CDMT
The Council for Dance, Drama and Musical Theatre (CDMT),...
- CDMT
The mechanism of DMTMM coupling is similar to other common amide coupling reactions involving activated carboxylic acids. [1] Its precursor, 2-chloro-4,6,-dimethoxy-1,3,5-triazine (CDMT), has also been used for amide coupling. DMTMM has also been used to synthesize other carboxylic functional groups such as esters and anhydrides.
- C₁₀H₁₇ClN₄O₃
- 276.72 g·mol−1
- 447-230-1
- .mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}3945-69-5
Las metalotioneínas (MTs) constituyen una familia de metaloproteína ricas en cisteína, generalmente de bajo peso molecular (entre 6000 y 10000 Da ). Se encuentran en el aparato de Golgi de las células (en el caso de vertebrados ).
CONTENTS. 4-Chlorodehydromethyltestosterone | C20H27ClO2 | CID 98521 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
29 de abr. de 2002 · Abstract. A simple procedure for the isolation of 2-hydroxy-4,6-dimethoxy-1,3,5-triazine (HO-DMT), a coproduct arising from dehydrating condensation using 4- (4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) has been established. HO-DMT can be recycled by treatment with POCl 3 to give 2-chloro-4,6-dimethoxy-1 ...
16 de sept. de 2019 · Ivabradine was included in the GDMT (class IIa) based on the SHIFT Trial 17 in which despite a 9‐bpm reduction in heart rate, no mortality benefit was shown, perhaps because of the underutilization of beta‐blockers. Only 26% of the patient in the SHIFT trial were on a target dose of beta blockers,11% were not on any beta blockers and 15% ...
